Improzo is an AI-native technology and advisory firm founded to serve the commercial, medical, and R&D functions of pharmaceutical and biotechnology companies. The company is incorporated in the United States and operates from offices in Boston, Massachusetts; California; and Pune, India, reflecting a hybrid onshore-offshore delivery model. Improzo was co-founded by Inderpreet Kambo (CEO) and Abhishek Trigunait (CTO), both of whom bring extensive backgrounds in life sciences digital transformation, AI-driven analytics, and large-scale technology programme delivery.

The company’s stated mission is to embed modular AI and automation into existing tools already in use across pharma organisations — including Veeva, Salesforce, and Snowflake — rather than replacing incumbent systems. Its model centres on deploying swappable intelligence layers atop these platforms to eliminate process inefficiencies, surface real-time insights, and accelerate commercial execution. Solutions are delivered through Improzo’s proprietary iZO platform in conjunction with embedded AI agents designed for life sciences-specific use cases.

Improzo’s client base spans emerging biopharma and established pharmaceutical companies, with its solutions applicable across commercial operations, medical affairs, and data science functions. The leadership team draws on institutional experience from IQVIA, ZS Associates, Takeda, Otsuka Pharmaceuticals, Veeva Systems, Accenture, Indegene, and EY, providing a depth of life sciences domain knowledge across analytics, CRM, and omnichannel strategy.

Key Products and Services

Customer Engagement Orchestration

• Omnichannel coordination across digital and field channels, personalised healthcare professional (HCP) journey design, and CRM workflow automation
• Delivered via the iZO Platform with embedded AI agents managing engagement sequencing, channel prioritisation, and next-best-action recommendations

Commercial AI Agents (Field Excellence)

• Incentive compensation AI for automated calculation, modelling, and compliance management
• Call reporting and CRM automation to reduce administrative burden on field teams
• Territory and account intelligence for real-time opportunity identification and call prioritisation
• Field coaching and enablement tools supporting rep performance management

CRM and Veeva Excellence

• Implementation, optimisation, and ongoing management of Veeva CRM and Vault environments
• CRM architecture design, data model configuration, workflow automation, and user adoption support
• Integration with Salesforce and other commercial systems

Intelligent Tech Transformation (Data, AI and BI)

• End-to-end data strategy and architecture for commercial and medical functions
• AI and machine learning model development, business intelligence (BI) dashboard build, and advanced analytics implementation
• Integration across data platforms including Snowflake, cloud data lakes, and third-party data sources

Medical Affairs AI

• AI-enabled tools supporting medical information management, scientific engagement planning, and key opinion leader (KOL) mapping
• Automation of medical affairs workflows including congress planning, publication tracking, and field medical team enablement

Voice Intelligence

• Voice-based AI solutions for field force automation, enabling hands-free call logging, CRM updates, and real-time coaching prompts via conversational interfaces

Improzo occupies the intersection of life sciences consulting and commercial technology, targeting a market where pharmaceutical companies are investing in AI-enabled commercial transformation but face challenges integrating new capabilities into existing CRM and data ecosystems. Its differentiation rests on a platform-agnostic, embeddable approach — rather than displacing Veeva or Salesforce deployments, Improzo layers AI agents and analytics atop them, reducing implementation friction and accelerating time to value. The leadership team’s collective pedigree across IQVIA, ZS, Takeda, and Veeva lends credibility in a sector where domain specificity and regulatory awareness are prerequisites for client confidence. As a relatively young firm, Improzo’s scale and client portfolio remain limited compared to established commercial technology providers, but its focused positioning within pharma commercial and medical affairs functions, combined with a growing suite of AI-native products, positions it as a specialist alternative to larger, broader-scope digital transformation vendors.